KR20240021888A - 표지 단계 동안 낮은 물 함량을 갖는 [18f] 방사성표지된 화합물을 제조하는 방법 - Google Patents
표지 단계 동안 낮은 물 함량을 갖는 [18f] 방사성표지된 화합물을 제조하는 방법 Download PDFInfo
- Publication number
- KR20240021888A KR20240021888A KR1020247001158A KR20247001158A KR20240021888A KR 20240021888 A KR20240021888 A KR 20240021888A KR 1020247001158 A KR1020247001158 A KR 1020247001158A KR 20247001158 A KR20247001158 A KR 20247001158A KR 20240021888 A KR20240021888 A KR 20240021888A
- Authority
- KR
- South Korea
- Prior art keywords
- water content
- ppm
- fluoride
- drying
- content during
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/041—Heterocyclic compounds
- A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K51/0459—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/041—Heterocyclic compounds
- A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K51/0453—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/041—Heterocyclic compounds
- A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K51/0463—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0491—Sugars, nucleosides, nucleotides, oligonucleotides, nucleic acids, e.g. DNA, RNA, nucleic acid aptamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0493—Steroids, e.g. cholesterol, testosterone
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/001—Acyclic or carbocyclic compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/002—Heterocyclic compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/004—Acyclic, carbocyclic or heterocyclic compounds containing elements other than carbon, hydrogen, halogen, oxygen, nitrogen, sulfur, selenium or tellurium
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/005—Sugars; Derivatives thereof; Nucleosides; Nucleotides; Nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/007—Steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physics & Mathematics (AREA)
- Medicinal Chemistry (AREA)
- Optics & Photonics (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Saccharide Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB2108605.3 | 2021-06-16 | ||
| GBGB2108605.3A GB202108605D0 (en) | 2021-06-16 | 2021-06-16 | Effect of water content |
| PCT/EP2022/066483 WO2022263594A1 (en) | 2021-06-16 | 2022-06-16 | Method for preparing an [18f] radiolabelled compound with low water content during labelling step |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20240021888A true KR20240021888A (ko) | 2024-02-19 |
Family
ID=76954450
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020247001158A Pending KR20240021888A (ko) | 2021-06-16 | 2022-06-16 | 표지 단계 동안 낮은 물 함량을 갖는 [18f] 방사성표지된 화합물을 제조하는 방법 |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US20240366808A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4355715A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2024522770A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20240021888A (cg-RX-API-DMAC7.html) |
| CN (1) | CN117500773A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2022294052A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112023026514A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3223802A1 (cg-RX-API-DMAC7.html) |
| GB (1) | GB202108605D0 (cg-RX-API-DMAC7.html) |
| IL (1) | IL308917A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2023015076A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2022263594A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201915206D0 (en) | 2019-10-21 | 2019-12-04 | Ge Healthcare Ltd | Use of cyclodextrins as a radiostabilizer |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0520527D0 (en) | 2005-10-10 | 2005-11-16 | Ge Healthcare Ltd | Automated method |
| EP2053033A1 (en) * | 2007-10-26 | 2009-04-29 | Bayer Schering Pharma AG | Compounds for use in imaging, diagnosing and/or treatment of diseases of the central nervous system or of tumors |
| AU2011213568B2 (en) | 2010-02-08 | 2016-05-12 | Lantheus Medical Imaging, Inc. | Methods and apparatus for synthesizing imaging agents, and intermediates thereof |
| EP2657213A1 (en) * | 2012-04-24 | 2013-10-30 | Institut National de la Santé et de la Recherche Medicale | Labelled quinoxaline derivatives as multimodal radiopharmaceuticals and their precursors |
| DK2880005T3 (en) * | 2012-07-30 | 2016-07-18 | Univ Denmark Tech Dtu | RADIO FLUOR RING PROCEDURE |
| WO2016086036A2 (en) * | 2014-11-25 | 2016-06-02 | Bristol-Myers Squibb Company | Methods and compositions for 18f-radiolabeling of biologics |
| US10716869B2 (en) * | 2016-02-29 | 2020-07-21 | Oncodesign Sa | Radiolabeled macrocyclic EGFR inhibitor |
| ES2907130T3 (es) * | 2017-09-26 | 2022-04-22 | Inst Nat Sante Rech Med | Darapladib radiomarcado, análogos del mismo y su uso como compuestos para la obtención de imágenes |
| GB201805253D0 (en) * | 2018-03-29 | 2018-05-16 | Ge Healthcare Ltd Ip | Solid phase extraction |
-
2021
- 2021-06-16 GB GBGB2108605.3A patent/GB202108605D0/en not_active Ceased
-
2022
- 2022-06-16 EP EP22734290.4A patent/EP4355715A1/en active Pending
- 2022-06-16 AU AU2022294052A patent/AU2022294052A1/en active Pending
- 2022-06-16 IL IL308917A patent/IL308917A/en unknown
- 2022-06-16 US US18/569,180 patent/US20240366808A1/en active Pending
- 2022-06-16 BR BR112023026514A patent/BR112023026514A2/pt unknown
- 2022-06-16 CN CN202280043075.0A patent/CN117500773A/zh active Pending
- 2022-06-16 CA CA3223802A patent/CA3223802A1/en active Pending
- 2022-06-16 MX MX2023015076A patent/MX2023015076A/es unknown
- 2022-06-16 KR KR1020247001158A patent/KR20240021888A/ko active Pending
- 2022-06-16 WO PCT/EP2022/066483 patent/WO2022263594A1/en not_active Ceased
- 2022-06-16 JP JP2023577714A patent/JP2024522770A/ja active Pending
-
2025
- 2025-06-09 US US19/232,774 patent/US20250312494A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| AU2022294052A1 (en) | 2023-12-14 |
| EP4355715A1 (en) | 2024-04-24 |
| MX2023015076A (es) | 2024-01-18 |
| GB202108605D0 (en) | 2021-07-28 |
| IL308917A (en) | 2024-01-01 |
| US20250312494A1 (en) | 2025-10-09 |
| CA3223802A1 (en) | 2022-12-22 |
| BR112023026514A2 (pt) | 2024-03-05 |
| WO2022263594A1 (en) | 2022-12-22 |
| JP2024522770A (ja) | 2024-06-21 |
| US20240366808A1 (en) | 2024-11-07 |
| CN117500773A (zh) | 2024-02-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2419096B1 (en) | Stabilization of radiopharmaceutical compositions using ascorbic acid | |
| JP7657759B2 (ja) | 新規製剤及び合成方法 | |
| Kämäräinen et al. | Preparation of fluorine‐18‐labelled fluoromisonidazole using two different synthesis methods | |
| US20250312494A1 (en) | Method for preparing an [18f] radiolabelled compound with low water content during labelling step | |
| US7018614B2 (en) | Stabilization of radiopharmaceuticals labeled with 18-F | |
| US20100228060A1 (en) | Perfluoro-aryliodonium salts in nucleophilic aromatic 18f-fluorination | |
| EP3757101A1 (en) | Process for producing fluorinated compounds using an alcohol solvent having an unsaturated hydrocarbon group | |
| KR101842989B1 (ko) | 카보닐기를 갖는 알코올 용매를 이용한 플루오르화 화합물의 제조방법 | |
| Wadsak et al. | 18F fluoroethylations: different strategies for the rapid translation of 11C-methylated radiotracers | |
| US20240350683A1 (en) | Preparation of a ph-adjusted ascorbic acid solution | |
| US10695450B2 (en) | Synthesis of a radioactive agent composition | |
| US10703726B2 (en) | Method for producing radiopharmaceutical composition | |
| JP7424574B2 (ja) | 放射性フッ素標識化合物の製造方法及び放射性医薬組成物の製造方法 | |
| WO2025114063A1 (en) | Stabilized method for 18f-labeling | |
| EP4559890A1 (en) | Stabilized method for 18f-labeling | |
| BE1031675B1 (fr) | Methode stabilisée pour le marquage au 18f | |
| JP6472493B2 (ja) | 放射性医薬組成物 | |
| Huang et al. | A two‐centre practical evaluation of [F‐18] FDOPA production methods and comparative dosimetry estimations based on in‐vivo microPET scans | |
| BE1024388B1 (fr) | Procede pour la preparation d'analogues de nitroimidazole a base de nucleoside radiomarques | |
| Vallabhajosula | Chemistry of Radiohalogens (F, Br, and I) | |
| Lee et al. | The synthesis of [36Cl]-,[82Br]-and [123I]-labelled 1-(3′-chloro-(bromo and iodo)-3′-deoxy-β-D-arabinofuranosyl) uracil | |
| HK1167344B (en) | Stabilization of radiopharmaceutical compositions using ascorbic acid | |
| HK1167344A (en) | Stabilization of radiopharmaceutical compositions using ascorbic acid |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
St.27 status event code: A-0-1-A10-A15-nap-PA0105 |
|
| PG1501 | Laying open of application |
St.27 status event code: A-1-1-Q10-Q12-nap-PG1501 |
|
| A201 | Request for examination | ||
| E13-X000 | Pre-grant limitation requested |
St.27 status event code: A-2-3-E10-E13-lim-X000 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| D21 | Rejection of application intended |
Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| PE0902 | Notice of grounds for rejection |
St.27 status event code: A-1-2-D10-D21-exm-PE0902 |